Seraxis

BioTech/Drugs - Germantown, Maryland, US

Seraxis Details

Seraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis’ lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis.

Seraxis logo, Seraxis contact details
Employees: 26
HQ: (240) 686-3595
Location: Germantown, Maryland, US
Revenue: $6 million
Cell therapy Cell encapsulation Regenerative medicine Stem cells
Seraxis Technologies
Email Providers

Gmail

Load Balancers

Nginx

CMS

WordPress.org

Other

Google Apps

View All Technologies Used At Seraxis

Contacting Seraxis: Connect with Executives and Employees

Get in Touch with Seraxis Executives and Employees

Connecting with Seraxis's Executives and Workforce

Accessing Contact Information for Seraxis Executives

Connecting with Seraxis: Reach Out to Their Team

Discover How to Contact Seraxis Executives and Staff

Looking to connect with Seraxis executives or employees?

Seeking to Get in Touch with Seraxis Executives or Staff?

Want to Reach Out to Seraxis Executives or Team Members?

In Search of Contact Details for Seraxis Professionals?

Connecting with Seraxis: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z